MapLight Therapeutics initiated with a Buy at TD Cowen

TD Cowen initiated coverage of MapLight Therapeutics (MPLT) with a Buy rating and no price target The company is advancing candidates for the treatment of central nervous system and neuropsychic conditions, the analyst tells investors in a research note. The firm says MapLight’s lead asset ML-007C-MA looks to improve upon Cobenfy’s profile in the treatment of schizophrenia with a Phase II readout set for Q3. TD views the shares as undervalued for the company’s schizophrenia opportunity alone.